Key facts
- This page summarizes RA CAPITAL MANAGEMENT, L.P.'s Form 4 filing for Hemab Therapeutics Holdings, Inc. (COAG).
- 15 reported transactions and 36 derivative rows are listed below.
- Accepted by SEC: 06 May 2026, 19:16.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Purchase
Purchase
Purchase
Purchase
Purchase
Purchase
Purchase
Purchase
Purchase
Purchase
Purchase
Purchase
Purchase
Purchase
Purchase
Purchase
Purchase
Purchase
Purchase
Purchase
Purchase
Purchase
Purchase
Purchase
Purchase
Purchase
Purchase
Purchase
Purchase
Purchase
Purchase
Purchase
Purchase
Purchase
Purchase
Purchase
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Additional SEC filing notes
Footnote F1
Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date.
Footnote F2
RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus Fund II") and RA Capital Nexus IV Fund, L.P. (the "Nexus Fund IV"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund II, the Nexus Fund IV, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
Footnote F3
Held directly by the Fund.
Footnote F4
Held directly by Nexus Fund II.
Footnote F5
Held directly by Nexus Fund IV.
Footnote F6
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.00 to $24.9994 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Footnote F7
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.495 to $24.455 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Footnote F8
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.505 to $25.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
SEC remarks
Dr. Laura Tadvalkar, a Managing Director of the Adviser, serves on the Issuer's board of directors.